期刊文献+

1例多种危险因素并存的肺栓塞患者的药学监护 被引量:1

Pharmaceutical care of a multiple risk factors coexisting in patient with pulmonary embolism
原文传递
导出
摘要 目的:通过对1例肺栓塞患者实施的药学监护过程,探讨临床药师在临床治疗中发挥的作用。方法:通过对患者进行入院前的用药情况调查、住院期间用药医嘱全程关注(尤其是抗凝治疗),为患者建立药历,协助医师为患者制订有效的个体化用药方案,患者出院后继续对其进行电话随访,了解患者INR稳定情况及病情,以评价药物治疗效果。结果:通过药师在整个过程中细致的药学监护及医嘱干预,避免了不良反应事件的发生,提高了患者治疗的依从性及药物治疗效果。结论:临床药师积极开展药学监护,协同临床医师优化给药方案,有利于患者的用药安全有效。 OBJECTIVE To explore the role of clinical pharmacist in the clinical drug treatment through the implementing pharmaceutical care process in a patient with pulmonary embolism. METHODS By the surveys on drug use before admission and full attention to the prescription medication during hospitalization (especially anticoagulant therapy), the patient's medica- tion history was established to assist physicians to develop effective individualized regimen. In order to understand the situation and the patient's INR stable condition and the effects of drug treatment, the telephone follow-up was continued after patient discharge, and then we could evaluate the effects of drug treatment. RESULTS The meticulous pharmaceutical care and medi- cation intervention by pharmacist in the whole process avoid the occurrence of adverse events and improve the effects of drug treatment. CONCLUSION The clinical pharmacist actively carries out pharmaceutical care, collaborates clinicians to optimize dosing regimens, which are conducive to patients with safe and effective medication.
出处 《中国医院药学杂志》 CAS CSCD 北大核心 2014年第19期1679-1681,共3页 Chinese Journal of Hospital Pharmacy
关键词 肺栓塞 华法林 基因检测 药学监护 危险因素 pulmonary embolism warfarin gene test pharmaceutical care risk factors
  • 相关文献

参考文献7

二级参考文献35

  • 1吴熙瑞.避孕药临床应用40年回顾与展望[J].中国实用妇科与产科杂志,2005,21(1):1-4. 被引量:22
  • 2胡大一,孙艺红.血栓栓塞性疾病的规范防治——ACCP最新溶栓和抗栓指南的启示[J].临床荟萃,2005,20(15):841-843. 被引量:16
  • 3许俊堂.口服抗凝药的作用机制与临床应用(下)[J].中国医刊,2006,41(2):52-53. 被引量:8
  • 4Jordan WM,Anand JK.Pulmonary embolism[J].Lancet,1961,278(18):1146-1147.
  • 5Marks L."Not just a statistic":the history of USA and UK policy over thrombotic disease and the oral contraceptive pill,1960s-1970s[J].Soc Sei Med,1999,49(9):1139-1155.
  • 6Spitzer WO,Lewis MA,Heinemann LA,et al.Third generation oral contraceptives and risk of venous thromboembolic disorders:an international case control study.Transnational Research Group on Oral Contraceptives and the Health of Young Women[J].BMJ,1996,312(7023):83-88.
  • 7Lidegaard O,Edstrfim B,Kreiner S.Oral contraceptives and venous thrombeembolism.A case-control study[J].Contraception,1998,57:291-301.
  • 8Bloemenkamp KW,Rosendaal FR,Helmerhorst FM,et al.Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects[J].Arch Intern Med,2000,160(1):49-52.
  • 9Hennessy S,Berlin JA,Kinman JL,et al.Risk of venous thromboembolism from oral contracep tives containing gestodene and desogestrel versus levonorgestrel:a metaanalysis and formal sensitivity analysis[J].Contraception,2001,64(2):125-133.
  • 10Lidegaard φ,Lφkkegaard E,Svendsen AL,et al.Hormonal contraception and risk of venous thromboembolism:national follow-up study[J].BMJ,2009,339:b2890.

共引文献1859

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部